Back to the main directory
EarningsReview / Equity
- Ready to Rumble by BNP Paribas Exane
- Just getting started by BNP Paribas Exane
- Per Aspera Ad Astra by BNP Paribas Exane
- Credit downgrade, factoring next? by BNP Paribas Exane
- Strong H1 FCF, but our view for FY25 remains unchanged by BNP Paribas Exane
- Growth optionality over medium-term by BNP Paribas Exane
- H1''23: Good profitability, uncertain outlook by BNP Paribas Exane
- Europris (Buy, TP: NOK80.00) - Eyeing Q3 gross margin recovery by DnB Markets
- Valuation update by DnB Markets
- Hosted Investor Meetings: Captaining the Cockpit by BNP Paribas Exane
- Roadshow feedback: Returns in Eastern Europe still attractive by BNP Paribas Exane
- iPhone 15 launch in-line by BNP Paribas Exane
- Prices, volumes, arbitrage opportunities, and implications on company profits by BNP Paribas Exane
- INVEST SECURITIES – OSE IMMUNOTHERAPEUTICS : Un rappel médiatique qui fait du bien à Tedopi - ACHAT, OC 8,3€ by Invest Securities
- INVEST SECURITIES – TME PHARMA : Accumule les preuves et les très bonnes données ! - ACHAT, OC 4,2€ by Invest Securities
- Groupe Crit - Conforme dans la tendance bien qu’un peu en dessous by MidCap Partners
- Sidetrade - Half-Year Results by MidCap Partners
- Esprinet - H1 2023: Unfavorable Economic Context by MidCap Partners
- Esprinet - S1 2023: Conjoncture Défavorable by MidCap Partners
- Respiri - Access platform-led growth prospects ahead by Edison Investment Research
- INDITEX: 2Q’23 RESULTS (ANÁLISIS BANCO SABADELL) by Sabadell
- Gruppo MOL - 2Q23 RESULTS PROVIDE GREATER VISIBILITY TO FY23 by Equita Sim
- Sunner Development (002299 CH) by HSBC
- Kingsoft Office (688111 CH) by HSBC
- FQ3''23 preview: A pit stop on the way to the Max by BNP Paribas Exane